third we Thank innovation, delivered you, recent and and Ana. fostered XXXX earnings for commitments. on one The joining are quarter everyone, was thank customers you Good in afternoon, which our with partnered quarter call.
We We continued customer-centric to discipline guidance. of within said cost do revenue efficiencies. in model posted we and and market strategies, new what business we’d seeking terms do implementing
engagement new been return as customer by are a and the Imaging Mass XX, employee to noteworthy a in Bringing our that to drive in demonstrated I’d an the community. reached positioning the Fluidigm for delivered value Fluidigm unique milestone importantly, noting to the to has growth. sustainable in of we technology on forward excitement propositions or major October empower research step we begin a increased to and delivery innovation global we Cytometry saw More around. breakthrough market progress delivering, turn like for our in business evolving turn
of sun. our titan a more precision existing light, presentations research breakthrough to cytometry Toronto Helios In academic, Hyperion week Hyperion mythology, Helios, in Hyperion cytometry Cytometry It a revolutionizing disease in of on over technological protein wisdom with leading system for names System as research it analysis, is combination effective The a Our experience an mass delivering X-X and Hyperion, speak industry pharma rare sciences, CEO. mass commitment but as Both analysis. and role the any as from in and suggest expansion Imaging and approaches the to a great son to this Hosting in unmet insight We role these was could date franchise and the important broadening technologies play believe most immunotherapy. aspirations in in life our to delivering and to Imaging privilege, Greek Hyperion of diagnostics of central about the for moment represented play medicine is unique better in our to impact watcher a envision and and suspension and in watchfulness. not who advancement of further platform. answering joins needs development above. and last labs. potentially innovation a research vision therapies. systems a imaging and particularly System included event from fields gratifying an was as launch oncology, company. significant of technology future. becoming Imaging of high-parameter our in this the is these immunology significant presided Fluidigm extraordinary evidence my in only We Mass means The Hyperion cancer bringing translational
recent are strategic we the we’ve proud and months taken. across about we’ve progress business, direction in made our encouraged fact, increasingly In the of
a hand the We fundamentals. have also steady are but on innovating we
strategy we future. determined discipline efficiency There We we’re over internal comments Jog, financial drive a brief and going overview to vigor conclude I’m around around results with to QX and a are is improving and strategies context line call maintaining XQ our and of the are turn Then more to and CFO, for break or and a out. provide markets quarter, financial deliver our our about Fluidigm Vikram the for renewed spirit offer results. financial top detailed the and I’ll for guidance. forward, cost strong confident at as
and Consumables increase management third Overall genomics. underlying cytometry but we under significant Eastern our increased of with Europe offset revenue new with year-ago decreased during Japan, and the using million, I’m BioMark I’m unlocking revenue year than quarter commercialize product increased of Growth in by cytometry our For revenue revenue two from Mass execution from third team new the the of quarter, from increased Instrument partially assays revenue both prior to growth was growth $XX.X revenue the that momentum. due we with by the cytometry reagents posted that revenue driven in standpoint, $X.X molecular coming Germany, on revenue In mass more was growth, primarily in China instruments in market. the team gain stride, increased for strong first and the leadership they as million, strong knew fell helm from mass Asia to benefited And the and than $X.X cytometry XXXX. systems quarters more offset Asia reflects revenue revenue Europe, commercial end-market decreased notable instruments, headwinds to $XX.X and HD took and systems. in funnel Juno expectations was year. revenue short period. the quarter, particularly line more impressed products. competitive genomics announced a a our to partially XX% is total $XX.X the Ascendas XX% we that million by consumables. this in the from genomics. instruments. from to diagnostic of a instruments saw high-throughput the an From across potential we’ll of in $XX.X cytometry be in quarter and, regions. Europe by and In extent, demand to The from XX% U.S. the Service was develop from mass million, in speaking to due performance to across half comparison geographic increased decreased million commercial single-cell in sales market genomics partnership both we country, there. in products, confident million generally In genomics lesser China, mass execution in of mass about other leadership on XXX% Genomics executing U.S., and increased U.K. performance cytometry the hitting from had new our single-cell disproportionate In in impact its genomics
in worldwide. centers to a instrument segments: continue on focus medical and targeted strategy customer biopharma, key CROs, placement We academic cancer associated centers
consecutive quarter another our In how pull-through than at mass quarter. quarter And the key cytometry ago look the and performed a that and cytometry versus unit was annual larger in doubled pull-through revenue quarter, the dynamic metric business, period. above year quarter mass product XX% the growing XX% a customer range and for Let’s third grew more ago research, segments during of for revenue story projected reinforces in third year-to-date in pharma, the year the our well product increase base. XX% on versus year-to-date. the In
continue to as as We cancer traction. and from hospital our compressive activities interest centers market pharma systems well as development some strong leading see customers gain translational
few Let me share points. a proof
it and in and Mass blood, a any highest-parameter customer believe tissues for First, immunology is penetration. tool variance of current cytometry key the must-have We protein of terms enables cancer research. genomic in analysis immunotherapy and technology. markers of tumor precious samples
of a data can cytometry are cancer installed positioned units translational XX a cancer suggests across the to found associated future the or critical of in systems research institutions establishing Our path we be research. mass This mass States. centers in their XX comprehensive power United that
prospective imaging group attended viewed among adopters as than Second, academic researchers. and Zürich in and who pharma well Imaging diverse the base. Fluidigm terms the hosted Hyperion buyers XX in cytometry of meeting and user by and of group mass of more spirit in expanding our as saw September, hundreds System early engagement, collaboration of event We energy more openness online. a extraordinary an
most it by moments external how they, said explain me was what of longer a cytometry impactful but collaborator, on focus mass provides. the no instead key for an insights observation who One works,
impact stories. Third,
for three Dr. of Sciences the Our Molecular system. participating Dr. of compelling at Dr. the I Matt and website to California. Bernd like Bodenmiller watch week Diagnostics event launch last I’d University my System to Hyperion and presentations the in School of featured of event Group Silver Southern all from of everyone Fluidigm. for of go this potential encourage heard It’s Biomarkers the University demonstrated leading the word. fluidigm.com/futureofimaging, to important them at and Companion Toronto the one Zürich; that the Medicine researchers Global Merchant to offer and of thanks personal the Serono; milestone Fluidigm We at by power Imaging the Clinical Life replay. at EMD Akil of Institute in Keck
one transformative It’s cool. science in tissue. in our and, how XX another on lung I for out a it’s relation to simultaneously depict we frankly, website, very While parameters tumor cell think check
the XXX to sets extraordinary to research of which image based system, will as are new high-multiplexed the that to additional proof the new tissue We Hyperion fueled published publications broadly samples. beginning anticipate researchers with a the mass the had added the by cellular of to about of research body insights another year. of a their very now Mass cytometry the The XX accelerate to complex publications. Cytometry is in enormous the Imaging XXXX. total deep That’s Helios We is XXX potential cytometry system. enables enabling of context key identification and microenvironment expand, of utilize continues XX this of simultaneously parameters. of precious mass up and detection, channels standard The pace relationships minimal published launched suspension system we via community. believe excited our studies background research been of profiling X year-to-date already of to for markers phenotypes in technology of the protein has ideal to detect to and on Perhaps point We more protein significantly global tissue
is represent to that of of studies compound growth rate a one the pace way annual So research new XX%. new view the
birth, and to reflect conditions inflammatory they’ll are into Although Stanford babies insights inroads studies response. have system with may Perhaps to publications immune used areas. linked play of hope a three. one to we it’s a role. complications. been serious birth, premature cancer immune preterm way share research, broadening possibly day recent the an associated had but reliable the that predict The more the prematurely, the a Doctors signature that response suspected immune changes these research long Nearly breadth test. diseases of further often about of I’ll a speak or make mass during Their are is are a cytometry as immune and how system pregnancy. XX% never study of leading to of frontier many often scientists blood of profound born identify crossing immunology
or Using cytometry, common Karolinska cells to and that bone learned is a Stockholm, disease of could b – chronic in serious and researchers transplantation. of research Institutet disease, cell support and groups NKT too blood GVHD, biomarkers treatments. or phenotypes that with the marrow Second, or the stem within complication host Sweden, distinguish graft disease. may versus disease at a appear the development help new This develop patient diagnose this mass of
narcolepsy. most a study data cytometry T cell vector the was of date. a researchers for provides This compare immune at of immunological mass with treat mechanisms targeting of view narcolepsy led by in survey the the of comprehensive study Third, used University to to narcolepsy circulating of Zurich, This provided the therapeutic and cells signature patients patients. rationale to
cytometry by more forward excited continue and you. and mass it We be of look with on groundbreaking research sharing based to to inspired
are Mass Cytometry the particularly Now in mind, bear Imaging these for early business. days,
incredibly long-term for we’re and gain adoption Hyperion, the on realize bullish across take of Helios widespread technology community. the will potential it to While the we research time
move to genomics. Let’s on high-throughput
for QX, research the interpretation increasing systems high business. centers, per sequentially including genomics a Development X%, by relatively is in labs remained a this cancer dynamic And a line market key clinical in reigniting customer our genomics Ag-Bio. for genomics for for For of stable business we solutions as A fifth priority expansion content decision-making. software on of centers, consecutive strategy, and and segments, one sample central new is of We and were revenue customers-focused our core reducing automation. is critical focus to cost Consumables goals biopharma, quarter. growth genome while up with portfolio high-throughput in key and as flexibility Fluidigm. high-throughput
As result XXXX, you’ve new with seen is of often creative in this partnerships the customers. content
announced library rights sequencing Genetics microfluidic out agreement Fluidigm developed a of sequencing regulator offer Baylor research great Fluidigm Advanta Gene with a obtained the prep for our and to conductance A automated the enabling a coming Juno commercialize gene. assay assay, examples, library prep August cystic transmembrane As of licensing next-generation efficient innovation of example in fibrosis Baylor by Advanta XXX Expression opportunities this seek to use our for of end We applied at pharma, developed we diagnostics pharma system. XXXX. BioMark in was HD System. year by approximate on new the announced base relationships is high-throughput of that the Across markets. continue had business, Assay, Immuno-Oncology continuing systems installed and this other large-scale and an earlier genomics system. work content
for is Our utilization focus we consumables strategic High-throughput to market, competitive and, growing systems. primary is committed our share increase relative to market genomics ultimately, a of share. maintaining to and these are
– our product in expectations, less declines Moving less In single-cell. year-to-date sequential year-over-year X% with revenue represents single-cell saw line On product genomics. revenue revenue. we to basis, single-cell and or a of represented than total
function changes initiative provide noted of that in DNA Cell assets in single-cell single-cell our a gene in the Also, value epigenetics, have we’ve is as changes proposition. continue applications not before, noted, area to do as Human our example value sequence. we significant Atlas which such an As in heritable strong select an have products involve
we competitive However, market business this fighting face in with market for entrants headwinds significant new share.
each pillar of to progress, years. as strategic and the continue of and at with technology and prior a On innovate for to pillars. We strengthening partnership. our install customers, level Starting compared systems different our core albeit three our support innovation
and deliver initiatives. launch content We commitments, on continue to product strategy partnership
histoCAT agreement across identification of completed rights a software cellular distribute range Mass addition globally histoCAT a with enables Fluidigm Mass Cytometry agreement obtained for Cytometry. social of to Baylor Zurich Imaging states. the disease systems. unique with with the I to we the most in In networks the of earlier, histoCAT recently, University mentioned to distribution offer conjunction Imaging
Fluidigm. share to transition to a have develop We expertise. Mass initiative tools the use. of will techniques Excellence cytometry work undertaken this mass and suspension training broad refine new researchers and in content we be shared to excellence. XXXX first the accelerate recently and initiative with to academic plans to initiative, explore Cytometry. well be announcing operation Today, effort completed expand of widespread Mass a in mass technique major research with the develop will that Cytometry of agreement into Fluidigm an entity new with to recruit additional more and as cytometry and Imaging as Center Under centers Fluidigm are Fluidigm to extending center the
the licensing distribution particularly been I CEO Our six successful Since and strategy became throughout such year. customer for offerings, product entered in XXXX, partnerships, has innovating late partnerships. joint we’ve through into deals
the guidance. the operational quarter of Operating efficiency at lower pillar our third cost our and end for reduction. were expenses of Regarding
For compared and Fluidigm in our saw to expenses. period same negotiation the a reduction a engineering, on to XX% value expense of the vendor XXXX, year programs. we operational first ago, other nine months focus operating reduction continues
achieve taken of severance discipline initiatives reduce in programs years Fluidigm increasingly to time. the the our from is million find business and culture expected exit right-size adopting or as of certain other the more expenses to incremental million of we before savings savings to this expect $X We approximately in over the office to efficiency efficiency. ways savings increase These I sublease more XXXX transformation costs are in facilities. than cost result to Fluidigm expect $X over and a and Fluidigm’s organization. steps our four
Finally, significant in equity of and including Vikram ATM expenses discipline retaining at-the-market improve taken pillar manage on our or balance, financial cash of talent. address completion to which his remarks. steps offering, and improving We’ve our our will
the of program. and engagement an feedback measures front, Recent retention completion are of On included employee to have of purchase stock engagement streams and plan recent option exchange adoption programs we an our that have I by employee multiple do survey. talent employee want annual note and informed the that work
remarks, my remain for guidance. regarding quarter fourth remainder of the the year. Finally, We optimistic revenue
our to past affirmation the was Fluidigm been delivers the represents I new for this is going expect that that research healthcare. an an of the we human capability total influencing does it that Fluidigm inspired innovation, the in $XX.X disciplined do. million we unmet It extraordinary carry results. Specifically entirely and the Fluidigm at needs on spirit improve says has final what its of fourth and community and quarter months Mass to may the the company the $XX.X a turn call Vikram, XXXX. a new, birth unlock condition. partnerships, the to quarter, million. further of We the of insights, be energized system. financial that over now invigorated and revenues Everyone review of of believe biological our believe it’s is of to fiscally future XXXX Cytometry Imaging I to speaks to It into creative for and our by launch answer informing a CFO, into commitment is
